Based on these preclinical evidences, a phase 2, multicenter, randomized, double-blind, placebo-controlled trial on Venglustat (GZ/SAR402671) was carried out in early PD patients who carried GBA mutations (ClinicalTrials.gov ID: NCT02906020; MOVES-PD Trial). Here, GBA1 is linked to Parkinson disease.